NASDAQ:TXMDTherapeuticsMD Stock Price, Forecast & News

TherapeuticsMD's stock was trading at $1.52 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TXMD shares have decreased by 17.8% and is now trading at $1.25. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TherapeuticsMD.

TherapeuticsMD is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for TherapeuticsMD.

TherapeuticsMD Inc (NASDAQ:TXMD) posted its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02. The business earned $12.25 million during the quarter, compared to analyst estimates of $11.48 million. TherapeuticsMD had a negative net margin of 333.88% and a negative return on equity of 1,170.63%. View TherapeuticsMD's earnings history.

TherapeuticsMD updated its first quarter 2020 After-Hours earnings guidance on Thursday, March, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $11 million, compared to the consensus revenue estimate of $11.64 million.

9 brokerages have issued twelve-month price targets for TherapeuticsMD's stock. Their forecasts range from $3.00 to $15.00. On average, they anticipate TherapeuticsMD's share price to reach $8.67 in the next year. This suggests a possible upside of 593.3% from the stock's current price. View analysts' price targets for TherapeuticsMD.

Headlines about TXMD stock have trended negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. TherapeuticsMD earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutTherapeuticsMD.

Some companies that are related to TherapeuticsMD include Tricida (TCDA), Cytokinetics (CYTK), ZEALAND PHARMA/S (ZEAL), Supernus Pharmaceuticals (SUPN), MacroGenics (MGNX), Phoenix Tree (IMAB), Revance Therapeutics (RVNC), Esperion Therapeutics (ESPR), Phathom Pharmaceuticals (PHAT), Kiniksa Pharmaceuticals (KNSA), Arcturus Therapeutics (ARCT), Myovant Sciences (MYOV), I-Mab (ARQT), Enanta Pharmaceuticals (ENTA) and Aimmune Therapeutics (AIMT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include Opko Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), Cleveland-Cliffs (CLF), NVIDIA (NVDA), CannTrust (CNTTF), Micron Technology (MU), Horizon Therapeutics (HZNP) and Novavax (NVAX).

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

TherapeuticsMD's stock is owned by a number of retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (7.10%), BlackRock Inc. (6.61%), Bank of New York Mellon Corp (4.67%), Franklin Resources Inc. (2.43%), C WorldWide Group Holding A S (2.28%) and State Street Corp (2.01%). Company insiders that own TherapeuticsMD stock include Angus C Russell, Brian Bernick, Daniel A Cartwright, Group L P Column, Jane F Barlow, John CK Iv Milligan, Jules A Musing, Robert G Finizio and Tommy G Thompson. View institutional ownership trends for TherapeuticsMD.

TXMD stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Invesco Ltd., Two Sigma Investments LP, Morgan Stanley, Greenwood Capital Associates LLC, JPMorgan Chase & Co., Bank of New York Mellon Corp, and BlackRock Inc.. View insider buying and selling activity for TherapeuticsMD.

TXMD stock was acquired by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, Nuveen Asset Management LLC, Geode Capital Management LLC, Twin Focus Capital Partners LLC, Bay Colony Advisory Group Inc d b a Bay Colony Advisors, Raymond James & Associates, Spark Investment Management LLC, and Arizona State Retirement System. Company insiders that have bought TherapeuticsMD stock in the last two years include Angus C Russell, Brian Bernick, Group L P Column, Jane F Barlow, John CK Iv Milligan, Robert G Finizio, and Tommy G Thompson. View insider buying and selling activity for TherapeuticsMD.

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TXMD stock can currently be purchased for approximately $1.25.

TherapeuticsMD has a market capitalization of $339.60 million and generates $49.65 million in revenue each year. The company earns $-176,150,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. TherapeuticsMD employs 348 workers across the globe.

The official website for TherapeuticsMD is www.therapeuticsmd.com.

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The company can be reached via phone at 561-961-1900 or via email at [email protected]